Search results
Showing 1151 to 1200 of 3030 results for all
Evidence-based recommendations on amivantamab (Rybrevant) with carboplatin and pemetrexed for untreated advanced non-small-cell lung cancer with activating EGFR exon 20 insertion mutations in adults.
Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis (CG95)
This guideline covers assessing and diagnosing recent chest pain in people aged 18 and over and managing symptoms while a diagnosis is being made. It aims to improve outcomes by providing advice on tests (ECG, high-sensitivity troponin tests, multislice CT angiography, functional testing) that support healthcare professionals to make a speedy and accurate diagnosis.
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]
In development Reference number: GID-TA10752 Expected publication date: TBC
In development Reference number: GID-TA11819 Expected publication date: 03 September 2026
we'd like to hear your views. This form is only for website feedback, for all other enquiries please contact us Loading form, please...
Evidence summaries: new medicines – Interim process statement (PMG1)
This interim process statement sets out to guide the development of 'Evidence summaries: new medicines' (ESNMs). It provides an overview of the key process principles and describes all stages of the development of ESNMs
Evidence-based recommendations on EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing.
This quality standard covers managing prostate cancer in people referred to secondary care or having follow-up for prostate cancer in primary care. It describes high-quality care in priority areas for improvement.
View quality statements for QS91Show all sections
Sections for QS91
- Quality statements
- Quality statement 1: Discussion with a named nurse specialist
- Quality statement 2: Treatment options
- Quality statement 3: Combination therapy
- Quality statement 4: Managing adverse effects of treatment
- Quality statement 5: Hormone-relapsed metastatic prostate cancer
- Update information
- About this quality standard
Acoramidis for treating transthyretin amyloidosis with cardiomyopathy (TA1121)
Evidence-based recommendations on acoramidis (Beyonttra) for treating wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.
Evidence-based recommendations on alteplase (Actilyse) for treating acute ischaemic stroke in adults.
Methadone and buprenorphine for the management of opioid dependence (TA114)
Evidence-based recommendations on methadone and buprenorphine (oral formulations) for managing opioid dependence in adults.
Evidence-based recommendations on using thrombolytic drugs (alteplase [Actilyse], reteplase [Rapilysin], streptokinase [Streptase] and tenecteplase [Metalyse]) for treating acute myocardial infarction in adults.
Elafibranor for previously treated primary biliary cholangitis (TA1016)
Evidence-based recommendations on elafibranor (Iqirvo) for previously treated primary biliary cholangitis in adults.
Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.
Nivolumab for previously treated advanced renal cell carcinoma (TA417)
Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults.
Surgery for stress urinary incontinence Patient decision aid ? 1 c NICE 2019. All rights reserved. Subject to Notice of rights. Last...
Compression products for treating venous leg ulcers: late-stage assessment (HTG758)
Late-stage assessment (LSA) guidance on compression products for treating venous leg ulcers.
View recommendations for HTG758Show all sections
This agreement constitutes the entire agreement between the Organisation and NICE relating to the Confidential Information
This agreement constitutes the entire agreement between the Organisation and NICE relating to the Confidential Information
Evidence-based recommendations on corticosteroid-eluting bioabsorbable stent or spacer insertion during endoscopic sinus surgery for chronic rhinosinusitis in adults. This involves putting a stent (short tube) into the sinus to improve drainage.
View recommendations for HTG407Show all sections
Balloon dilatation of systemic to pulmonary arterial shunts in children (HTG48)
Evidence-based recommendations on balloon dilatation of systemic to pulmonary arterial shunts in children. This involves inflating a balloon inserted into the area so blood can flow through more easily.
View recommendations for HTG48Show all sections
Sections for HTG48
NICE is committed to supporting the national agenda for achieving a sustainable health and care system.
The Debrisoft monofilament debridement pad for use in acute or chronic wounds (HTG334)
Evidence-based recommendations on the Debrisoft monofilament debridement pad for use in acute or chronic wounds.
NICE guidance and standards support health professionals by providing evidence-based recommendations that enhance clinical decision-making and patient care.
Information about medical technologies advisory committee registration and meetings
More detail about medical technologies advisory committee registration, meeting arrangements and types of attendee.
More detail about Diagnostics Advisory Committee (DAC) registration, meeting arrangements and types of attendee.
More detail about Diagnostics Advisory Committee (DAC) registration, meeting arrangements and types of attendee.
Information about medical technologies advisory committee registration and meetings
More detail about medical technologies advisory committee registration, meeting arrangements and types of attendee.
Evidence-based recommendations on nivolumab (Opdivo) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy in adults.
Antimicrobial prescribing: imipenem with cilastatin and relebactam (ES30)
Summary of the evidence on antimicrobial prescribing: imipenem with cilastatin and relebactam
In development Reference number: GID-TA11636 Expected publication date: 26 August 2026
Evidence-based recommendations on eptinezumab (VYEPTI) for preventing migraine in adults.
This guideline covers how general dental practice teams can convey advice about oral hygiene and the use of fluoride. It also covers diet, smoking, smokeless tobacco and alcohol intake.
Evidence-based recommendations on azacitidine (Onureg) for maintenance treatment of acute myeloid leukaemia after induction therapy in adults.
Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (HTG292)
Evidence-based recommendations on 3 electroencephalography (EEG)-based depth of anaesthesia monitors for assessing a patient’s response to anaesthetic drugs during surgery. The monitors are Bispectral Index (BIS), E-Entrophy and Narcotrend-Compact M.
Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating PD-L1-positive non-small-cell lung cancer in adults who have had chemotherapy.
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making
Evidence-based recommendations on new generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners.
Our guidelines make evidence based, best practice recommendations. These help to improve patient safety and reduce the risk of harm across the health system.
Evidence-based recommendations on balloon dilatation of pulmonary valve stenosis. This involves passing a small deflated balloon up through a blood vessel at the top of the leg and into the blocked area in the heart.
View recommendations for HTG40Show all sections
Sections for HTG40
Therapeutic percutaneous image-guided aspiration of spinal cysts (HTG143)
Evidence-based recommendations on therapeutic percutaneous image-guided aspiration of spinal cord cysts. This involves using a needle to drain the cyst and remove pressure on the spinal cord or nerve roots.
View recommendations for HTG143Show all sections
Sections for HTG143
Hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea (HTG455)
Evidence-based recommendations on hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea in adults. This involves implanting a device under the skin in the chest and connecting it to a nerve under the tongue (hypoglossal nerve).
Specialist neonatal respiratory care for babies born preterm (NG124)
This guideline covers specific aspects of respiratory support (for example, oxygen supplementation, assisted ventilation, treatment of some respiratory disorders, and aspects of monitoring) for preterm babies in hospital.
This guideline covers diagnosing, assessing, and treating community-acquired and hospital-acquired pneumonia, including bacterial pneumonia secondary to COVID-19, in babies over 1 month (corrected gestational age), children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.
This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.
Vutrisiran for treating hereditary transthyretin-related amyloidosis (TA868)
Evidence-based recommendations on vutrisiran (Amvuttra) for treating hereditary transthyretin-related amyloidosis in adults.
Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma in adults.
Show all sections
Each year we work with NHSE and the DHSC to prioritise topics for development.